Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Amylyx stock slips 6% after phase 2 rare disease data drop
After Relyvrio’s market withdrawal, Amylyx is sharing early phase 2 data in a separate rare disease.
Gabrielle Masson
Apr 10, 2024 2:48pm
ACC: Efficacy ticks down a smidge for Ionis' metabolic drug
Apr 7, 2024 9:45am
With new data in hand, Astria makes ph. 3 wish on shooting star
Mar 25, 2024 10:46am
Phase 2 fail sends OcuTerra's eye drop dreams down the drain
Mar 14, 2024 9:15am
Alumis hits stride as TYK2 inhibitor improves psoriasis in ph. 2
Mar 9, 2024 12:00pm
Vivoryon Alzheimer’s drug fails phase 2 trial, crashing stock
Mar 4, 2024 8:13am